November 29, 2022Gate Neurosciences doses first subject in a translational EEG biomarker study of apimostinel, a rapid-acting treatment for acute depressive disorderRead full post
September 29, 2022Gate Neurosciences publishes new data highlighting novel mechanism of lead rapid-acting oral antidepressant and provides business updateRead full post
August 23, 2022Gate Neurosciences emerges from stealth with a portfolio of next-generation therapies for central nervous system diseasesRead full post
Shekhar (2023): Aprison Lecture - Novel Approach to NMDA Modulation, Plasticity, Rapid Antidepressant Drugs
Duman (2020): Positive NMDAR modulation by Zelquistinel exerts rapid antidepressant-like effects via excitatory neurons
Zanos (2023): NMDAR activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine
Donello (2022): Zelquistinel is a novel oral NMDAR PAM exhibiting rapid and sustained antidepressant-like effects
